Having trouble accessing articles? Reset your cache.

Boehringer joins KRAS race with a molecule designed to block all mutations

Boehringer’s pan-KRAS blocker could treat more patients than leading compounds against KRAS G12C

Boehringer announced Tuesday that its SOS1:KRAS inhibitor BI 1701963 started Phase I testing, making it the latest company to enter the clinic with a KRAS inhibitor.

Unlike the Phase I/II molecules from Amgen Inc. (NASDAQ:AMGN) and Mirati Therapeutics Inc. (NASDAQ:MRTX) that selectively target the common KRAS G12C mutation,

Read the full 482 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE